Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $48,225 | $29,459 | $47,306 | $44,937 |
| G&A Expenses | $11,892 | $13,335 | $15,374 | $11,283 |
| SG&A Expenses | $11,892 | $13,335 | $15,374 | $11,283 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $60,117 | $42,794 | $62,680 | $56,220 |
| Operating Income | -$60,117 | -$42,794 | -$62,680 | -$56,220 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,266 | $5,252 | $655 | -$1,557 |
| Pre-Tax Income | -$55,851 | -$37,543 | -$62,025 | -$57,776 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55,851 | -$37,543 | -$62,025 | -$57,776 |
| % Margin | – | – | – | – |
| EPS | -0.94 | -0.64 | -1.06 | -1.07 |
| % Growth | -46.9% | 39.6% | 0.9% | – |
| EPS Diluted | -0.94 | -0.64 | -1.06 | -1.07 |
| Weighted Avg Shares Out | 59,485 | 58,943 | 58,406 | 54,042 |
| Weighted Avg Shares Out Dil | 59,485 | 58,943 | 58,406 | 54,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,192 | $7,323 | $2,349 | $185 |
| Interest Expense | $1,926 | $2,071 | $1,694 | $1,742 |
| Depreciation & Amortization | $250 | $263 | $259 | $264 |
| EBITDA | -$53,676 | -$35,208 | -$60,072 | -$55,770 |
| % Margin | – | – | – | – |